Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.

ABSTRACT:

Background

Pancreatic patient-derived organoids (PDOs) are a well-established model for studying pancreatic ductal adenocarcinoma (PDAC) carcinogenesis and are potential predictors of clinical responses to chemotherapy. Oncolytic virotherapy is envisioned as a novel treatment modality for pancreatic cancer, and candidate viruses are being tested in clinical trials. Here, we explore the feasibility of using PDOs as a screening platform for the oncolytic adenovirus (OA) response.

Methods

Organoids were established from healthy pancreas and PDAC tissues and assessed for infectivity, oncoselectivity, and patient-dependent sensitivity to OA. Antitumour effects were studied in vivo in organoid xenografts. Further evaluation of oncolytic responses was conducted in organoids derived

SUBMITTER: Raimondi G 

PROVIDER: S-EPMC7251378 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature